DHA / DOH / MOH exam (UAE) cardiology questions

ST elevation in leads II, III and aVF localizes injury to the inferior wall, supplied typically by the right coronary artery. Reciprocal ST depression in leads I and aVL (the lateral leads, electrically opposite to the inferior leads) supports an acute occlusive process rather than a diffuse or non-ischemic cause. Reciprocal changes increase the specificity of ST elevation for acute myocardial infarction. STEMI diagnostic criteria require ST elevation of at least 1 mm in two contiguous limb leads or 2 mm in contiguous precordial leads (age- and sex-adjusted), which is met here.

• A. Anterior injury would show ST elevation in V1-V4, not in II, III and aVF.
• C. Lateral injury would show ST elevation in I, aVL, V5-V6, not inferior leads.
• D. Pericarditis causes diffuse concave ST elevation without reciprocal depression and typically with PR depression.

For patients presenting directly to a PCI-capable hospital, current guidelines recommend a door-to-balloon time of 90 minutes or less for primary PCI. This target reflects the time-sensitive nature of myocardial salvage, since earlier reperfusion is associated with reduced infarct size and mortality. If the patient is transferred from a non-PCI-capable facility, the target extends to within 120 minutes of first medical contact. Systems of care, including pre-hospital ECG and catheterization lab activation, are designed to meet these benchmarks.

• B. 60 minutes is shorter than the guideline-recommended target and not the standard benchmark.
• C. 180 minutes exceeds the acceptable delay and is associated with worse outcomes.
• D. 120 minutes is the target for first medical contact to device time when transfer between facilities is required, not for a PCI-capable hospital.

When primary PCI cannot be performed within 120 minutes of first medical contact, fibrinolytic therapy should be administered within 30 minutes of arrival if there is no contraindication, followed by transfer to a PCI-capable center. This patient has no contraindications to fibrinolysis and the anticipated delay (150 minutes) exceeds the 120-minute threshold favoring a pharmaco-invasive strategy. Early reperfusion, even pharmacological, limits infarct size when mechanical reperfusion is not timely available. After fibrinolysis, the patient should still be transferred for rescue or routine early PCI.

• A. Beta-blockers do not achieve reperfusion and delaying reassessment risks further myocardial loss.
• B. Heparin alone does not achieve reperfusion and observation delays treatment in an evolving STEMI.
• C. Transfer alone without fibrinolysis would expose the patient to an unacceptable delay exceeding the 120-minute PCI target.

The key distinction between unstable angina and NSTEMI is the presence of myocardial necrosis, reflected by a significant rise in cardiac troponin above the upper reference limit. This patient's troponin rose from a normal value (8 ng/L) to a clearly elevated value (42 ng/L) with a delta exceeding the diagnostic threshold for myocardial infarction, confirming NSTEMI. Unstable angina presents with similar ischemic symptoms and ECG changes but troponin remains within the normal range on serial testing. The clinical picture (ischemic symptoms, dynamic T-wave changes, rising troponin) fits the universal definition of myocardial infarction.

• A. Prinzmetal angina is caused by coronary vasospasm with transient ST elevation, typically at rest, and does not fit this troponin pattern.
• B. Unstable angina requires troponin to remain normal on serial testing, which is not the case here.
• C. Acute pericarditis typically causes diffuse ST elevation and PR depression, not isolated T-wave inversion with a significant troponin rise.

Patients with NSTEMI classified as high risk by the GRACE score (generally greater than 140) should undergo early invasive coronary angiography within 24 hours of admission. This early invasive strategy reduces recurrent ischemic events compared with a delayed or conservative approach in high-risk patients. Immediate angiography within 2 hours is reserved for very high-risk features such as hemodynamic instability, refractory angina, or life-threatening arrhythmias, none of which are present here. Lower-risk patients can be managed with angiography within 72 hours or a selective invasive strategy.

• A. Elective outpatient angiography is inappropriate and delays treatment of a high-risk NSTEMI.
• C. Immediate angiography within 2 hours is reserved for very high-risk patients with ongoing instability, which this patient does not have.
• D. Angiography within 72 hours is appropriate for intermediate-risk patients, not this high-risk GRACE score.

Current guidelines recommend aspirin combined with a potent P2Y12 inhibitor such as ticagrelor or prasugrel as first-line dual antiplatelet therapy after ACS treated with PCI, as these agents provide faster and more consistent platelet inhibition than clopidogrel and reduce ischemic events. Ticagrelor is preferred over clopidogrel in the absence of contraindications such as prior intracranial hemorrhage or need for oral anticoagulation, in which case clopidogrel may be used instead. Dual antiplatelet therapy is generally continued for 12 months after ACS unless bleeding risk mandates a shorter duration. Aspirin alone is insufficient after stenting given the high risk of stent thrombosis.

• A. Clopidogrel is reserved for patients with contraindications to ticagrelor or prasugrel, or those needing triple therapy with anticoagulation.
• B. Aspirin alone provides insufficient protection against stent thrombosis after PCI.
• C. Warfarin is an anticoagulant, not an antiplatelet agent, and is not part of standard dual antiplatelet therapy after ACS.

ST elevation in II, III, aVF with V4R elevation indicates right ventricular (RV) infarction complicating inferior STEMI. The RV-infarcted myocardium is preload-dependent to maintain cardiac output, and nitrates cause venodilation that reduces preload, precipitating profound hypotension and cardiogenic shock. Aspirin, morphine, and clopidogrel do not have this preload-dependent mechanism and remain part of standard STEMI management. Intravenous fluids, not nitrates, are the initial treatment for hypotension in RV infarction.

• A. Clopidogrel is part of standard dual antiplatelet therapy in STEMI.
• B. Aspirin is standard antiplatelet therapy in STEMI and is not contraindicated here.
• D. Morphine may be used for pain relief and does not carry the same preload-dependent risk, though caution is used if hypotensive.

Sudden pulmonary edema with a new apical pansystolic murmur radiating to the axilla a few days after MI is classic for acute mitral regurgitation due to papillary muscle rupture, most often complicating inferior or posterior infarcts because the posteromedial papillary muscle has a single blood supply. The abrupt volume overload on an unprepared left atrium and ventricle causes rapid pulmonary edema and hypotension. Diagnosis is confirmed with urgent echocardiography, and treatment is emergency surgical repair or valve replacement with afterload reduction and intra-aortic balloon counterpulsation as bridge therapy. Pericarditis causes a friction rub, not a pansystolic murmur, and does not typically cause flash pulmonary edema.

• A. Reinfarction would present with recurrent chest pain and ECG changes, not a new murmur with acute pulmonary edema.
• B. RV infarction causes hypotension with clear lungs and elevated JVP, not pulmonary edema with a new murmur.
• C. Pericarditis presents with a pericardial friction rub and positional chest pain, not a pansystolic murmur or flash pulmonary edema.

Free wall rupture classically presents with sudden hemodynamic collapse and pulseless electrical activity or cardiac tamponade, as blood rapidly fills the pericardial sac and causes electromechanical dissociation, where organized electrical activity persists without an effective pulse. In contrast, ventricular septal rupture presents with a new harsh pansystolic murmur with a palpable thrill at the left lower sternal border and progressive biventricular failure, usually without sudden pulseless collapse. Free wall rupture is a surgical emergency requiring immediate pericardiocentesis and surgical repair, and most patients die before reaching the operating room. Papillary muscle rupture causes acute mitral regurgitation and pulmonary edema rather than tamponade physiology.

• A. Septal rupture causes a new murmur and biventricular failure, not sudden pulseless collapse with electromechanical dissociation.
• C. Papillary muscle rupture causes acute mitral regurgitation and pulmonary edema, not tamponade and sudden collapse.
• D. LV aneurysm develops over weeks and causes heart failure or arrhythmia, not sudden pulseless collapse.

Current guidelines recommend high-intensity statin therapy for all patients after myocardial infarction regardless of baseline LDL cholesterol, to achieve maximal atherosclerotic plaque stabilization and LDL lowering. Beta-blockers reduce mortality and reinfarction risk by lowering myocardial oxygen demand and reducing arrhythmic risk, and ACE inhibitors (or ARBs) are indicated post-MI, particularly with reduced ejection fraction, to limit adverse ventricular remodeling. Fibrates and loop diuretics have no proven mortality benefit in routine post-MI secondary prevention, and statins should never be delayed pending a repeat lipid check since benefit is independent of baseline LDL.

• B. Statin therapy should be started immediately post-MI regardless of LDL level, not deferred.
• C. Fibrates have no proven secondary prevention benefit post-MI, and calcium channel blockers are not first-line unless beta-blockers are contraindicated.
• D. A loop diuretic has no secondary prevention role unless there is volume overload; it is not part of standard post-MI therapy.

Typical angina is defined by three features: substernal chest discomfort of characteristic quality and duration, provoked by exertion or emotional stress, and relieved by rest or nitrates within minutes. This patient's pain meets all three criteria, consistent with typical stable angina from fixed coronary atherosclerosis limiting flow reserve during increased myocardial oxygen demand. Atypical angina meets only two of the three criteria, and non-cardiac chest pain meets one or none. Unstable angina is distinguished by pain at rest, new-onset severe pain, or a crescendo pattern, none of which are present here since his symptoms are stable and exertional over three months.

• A. Unstable angina involves rest pain, crescendo symptoms, or new severe onset, none of which this stable exertional pattern shows.
• B. Non-cardiac chest pain meets one or none of the typical criteria, unlike this fully exertional, reproducible, rest-relieved pattern.
• D. Atypical angina meets only two of the three defining criteria; this patient meets all three.

Sublingual GTN is used for acute relief of angina symptoms: the patient should sit down, administer one dose under the tongue at symptom onset, and may repeat a second dose after 5 minutes if pain persists. If symptoms continue 5 minutes after the second dose, this suggests a possible acute coronary syndrome, and emergency medical services should be contacted immediately. GTN is absorbed sublingually and must not be swallowed, as hepatic first-pass metabolism would inactivate it. Prophylactic once-daily dosing is not how sublingual GTN is used, and waiting 30 minutes before treatment would delay symptom relief and risk progression to infarction.

• A. Swallowing GTN subjects it to hepatic first-pass metabolism, destroying its effect; it must be absorbed sublingually.
• B. Treatment should begin promptly at symptom onset, not after a prolonged delay, since persistent pain may indicate acute coronary syndrome.
• C. Sublingual GTN is used for acute symptom relief, not as a scheduled once-daily prophylactic dose.

This patient has diabetes plus an estimated 10-year ASCVD risk above 20%, placing him in the high-risk category for primary prevention. Current guidelines recommend high-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) for high-risk primary prevention patients to achieve at least a 50% reduction in LDL-cholesterol. Low or moderate-intensity statins produce smaller LDL reductions and are reserved for lower-risk individuals. Ezetimibe and fibrates are not first-line monotherapy for primary ASCVD prevention.

• A. Fibrates primarily lower triglycerides and are not indicated as first-line therapy for LDL-driven ASCVD risk reduction.
• C. Ezetimibe is an add-on agent, not first-line monotherapy for primary prevention in a high-risk patient.
• D. Low-intensity dosing is insufficient for a high-risk patient requiring at least 50% LDL reduction.

Cigarette smoking is a major modifiable cardiovascular risk factor that directly damages the vascular endothelium, promotes atherosclerosis, and increases thrombotic risk. Smoking cessation counseling and pharmacotherapy should be prioritized in any cardiovascular risk assessment because quitting produces a measurable reduction in cardiovascular events within one to two years. Family history, sex, and age are non-modifiable risk factors that inform overall risk stratification but cannot be targeted by intervention.

• A. Family history is a fixed, non-modifiable risk factor used for risk stratification only.
• B. Sex is a non-modifiable demographic risk factor.
• D. Age is a non-modifiable risk factor that increases baseline cardiovascular risk.

An elevated natriuretic peptide in a patient with signs and symptoms of heart failure should be followed by transthoracic echocardiography, which directly measures left ventricular ejection fraction and identifies structural abnormalities such as chamber dilation, wall motion abnormalities, and valvular disease. This distinguishes heart failure with reduced ejection fraction from preserved ejection fraction and determines eligibility for guideline-directed medical therapy. Chest radiograph and ECG support the diagnosis but do not quantify ejection fraction. Coronary angiography assesses coronary anatomy but is not the initial test to establish the heart failure phenotype.

• B. Chest radiograph may show pulmonary congestion or cardiomegaly but cannot quantify ejection fraction.
• C. ECG may show arrhythmia or ischemic changes but does not assess ventricular function directly.
• D. Coronary angiography evaluates coronary anatomy, not ejection fraction, and is not the first-line test for diagnosing HFrEF.

Clinical diagnostic frameworks such as the Framingham criteria classify a third heart sound, elevated jugular venous pressure, and pulmonary crackles as major criteria for heart failure, and the combination of multiple major criteria strongly supports the diagnosis. Isolated peripheral edema, weight gain, or mild tachypnea alone are minor or nonspecific findings that occur in many other conditions and are insufficient alone to establish the diagnosis. Combining major and minor criteria improves diagnostic accuracy at the bedside before confirmatory imaging or biomarker testing. This patient's combination of major criteria meets the threshold for a clinical diagnosis of heart failure.

• A. Isolated weight gain is a minor criterion and insufficient alone for diagnosis.
• B. Mild tachypnea alone is nonspecific and not diagnostic without supporting major criteria.
• D. Ankle edema alone is a minor, nonspecific criterion seen in venous insufficiency and other conditions.

Current heart failure guidelines recommend the four pillars of guideline-directed medical therapy for HFrEF: an angiotensin receptor-neprilysin inhibitor (or ACE inhibitor/ARB if unavailable), a beta-blocker, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor. These four drug classes each independently reduce mortality and hospitalization in randomized controlled trials and should be started and up-titrated as early as tolerated, often simultaneously or in rapid sequence. Digoxin and diuretics manage symptoms but do not reduce mortality. Calcium channel blockers are generally avoided in HFrEF due to negative inotropic effects, and nitrate-hydralazine is reserved for specific populations such as African American patients who remain symptomatic on standard therapy or who cannot tolerate renin-angiotensin system blockade.

• A. Nitrate-hydralazine is an add-on option for specific subgroups, not first-line monotherapy for all HFrEF patients.
• B. Digoxin and loop diuretics improve symptoms and reduce hospitalizations but do not reduce mortality and are not first-line foundational therapy.
• D. Calcium channel blockers have negative inotropic effects and are generally avoided in HFrEF; thiazides are not foundational mortality-reducing therapy.

This patient has acute pulmonary edema with hypoxia, and immediate management requires supplemental oxygen to correct hypoxemia along with intravenous loop diuretics such as furosemide to reduce pulmonary congestion through venodilation and natriuresis. Beta-blockers are avoided during acute decompensation because of their negative inotropic effect, which can worsen hemodynamic instability. Fluid boluses would worsen volume overload in a congested patient. Delaying treatment for outpatient follow-up is inappropriate given the severity of this presentation, which requires emergency department management and likely hospital admission.

• A. Beta-blockers should not be initiated or continued acutely in decompensated heart failure due to risk of worsening hemodynamics.
• B. An intravenous fluid bolus would worsen volume overload in a congested patient.
• D. This presentation represents an emergency requiring immediate treatment, not delayed outpatient review.

Discontinuation of diuretic therapy is one of the most common and directly identifiable precipitants of acute heart failure decompensation, as it leads to rapid fluid retention and recurrence of congestive symptoms. Recognizing non-adherence as a precipitant is important because it is reversible and preventable through patient education, medication reconciliation, and addressing barriers to access. The clinical history in this patient, stopping diuretics just before symptom onset, directly points to non-adherence rather than an unrelated acute illness. Other precipitants such as infection, arrhythmia, myocardial ischemia, and thyroid dysfunction should still be screened for but are not supported by this patient's history or findings.

• A. There is no fever, viral prodrome, or supporting history to suggest myocarditis.
• B. There are no clinical features such as tremor, weight loss, or tachycardia to suggest thyrotoxicosis.
• C. There are no findings such as pleuritic chest pain, hemoptysis, or risk factors pointing to pulmonary embolism.

ACE inhibitors can cause a rise in serum creatinine due to reduced glomerular filtration pressure and can cause hyperkalemia due to reduced aldosterone-mediated potassium excretion, so renal function and serum potassium should be checked within 1-2 weeks of initiation and after each dose up-titration. A modest rise in creatinine of up to 30% from baseline is acceptable and does not require stopping the drug, but ongoing monitoring guides whether dose adjustment is needed. Discontinuing the drug without checking labs would prematurely withdraw a mortality-reducing therapy. Empirically adding potassium or switching to a calcium channel blocker without first assessing renal function and potassium is not evidence-based practice.

• B. Switching therapy without laboratory assessment is not guideline-directed monitoring practice.
• C. Discontinuing therapy without first checking labs risks inappropriately withdrawing a mortality-reducing medication.
• D. Empiric potassium supplementation is inappropriate and could cause dangerous hyperkalemia if levels are already elevated.

This patient has clinical signs and symptoms of heart failure with an ejection fraction of 50% or higher, structural abnormality (left atrial enlargement), elevated filling pressures (E/e' ratio), and elevated natriuretic peptide, meeting criteria for heart failure with preserved ejection fraction. HFrEF is defined by an ejection fraction of 40% or less. Mildly reduced EF falls in the 41-49% range. High-output failure occurs with conditions like severe anemia or thyrotoxicosis and is not suggested here.

• B. Mildly reduced EF refers to a range of 41-49%, which does not match this patient's EF of 58%.
• C. HFrEF requires an ejection fraction of 40% or less, not 58%.
• D. High-output failure requires a hyperdynamic state such as severe anemia or thyrotoxicosis, with no evidence of either here.

Cardiorenal syndrome type 1 occurs when aggressive diuresis for acute decompensated heart failure leads to intravascular volume contraction, reduced renal perfusion, and a rise in creatinine, often accompanied by clinical improvement in congestion. The temporal relationship with diuretic intensification and the absence of fever or urinary symptoms supports this diagnosis over a primary renal process. Management involves balancing decongestion against renal perfusion, sometimes requiring diuretic dose adjustment. Acute interstitial nephritis typically presents with fever, rash, and eosinophilia, which are absent here.

• B. There is no mention of recent contrast exposure, making this diagnosis unlikely.
• C. Interstitial nephritis from furosemide typically presents with fever, rash, or eosinophilia, none of which are described.
• D. Pyelonephritis would typically present with fever, flank pain, or urinary symptoms, which are absent.

Atrial fibrillation is characterized by chaotic atrial electrical activity producing an irregularly irregular rhythm with absent discrete P waves and a fibrillating baseline. Atrial flutter typically shows a sawtooth flutter wave pattern with a more regular ventricular response unless block is highly variable. Multifocal atrial tachycardia shows at least three distinct P wave morphologies, which is a different pattern from absent P waves. Sinus tachycardia with ectopics would show visible sinus P waves with occasional premature beats rather than a continuously irregular rhythm.

• A. Multifocal atrial tachycardia requires at least three different P wave morphologies, not absent P waves.
• B. Sinus tachycardia would show regular sinus P waves except during occasional ectopic beats, not a continuously irregular rhythm.
• D. Atrial flutter classically shows sawtooth flutter waves, not an absent P wave baseline.

A CHA2DS2-VASc score of 2 or more in women (or 1 or more in women beyond the sex category point, per some guideline interpretations, generally 2 or more overall) indicates a significant stroke risk that warrants oral anticoagulation according to current international guidelines. This patient's score of 4 clearly exceeds the threshold for anticoagulation regardless of rhythm control strategy. Aspirin alone is no longer recommended for stroke prevention in atrial fibrillation due to inferior efficacy compared to anticoagulants. Delaying treatment or withholding anticoagulation would expose her to unnecessary stroke risk.

• A. Aspirin monotherapy is not recommended for stroke prevention in atrial fibrillation due to inferior efficacy compared to oral anticoagulants.
• B. A score of 4 indicates significant stroke risk; withholding anticoagulation is inappropriate.
• C. The diagnosis is already confirmed; delaying anticoagulation decision increases stroke risk unnecessarily.

In a hemodynamically stable patient with atrial fibrillation of clearly known onset within 48 hours, cardioversion (electrical or pharmacological) can be performed without the need for prior anticoagulation or transesophageal echocardiogram, as thrombus formation is unlikely in this short window. Rate control alone is a reasonable alternative strategy but rhythm control is preferred in a young, symptomatic patient with a first episode and no structural heart disease to restore sinus rhythm. Delaying for 3 weeks of anticoagulation is the approach used when onset is unknown or exceeds 48 hours. Transesophageal echocardiogram is reserved for cases where onset is uncertain or beyond 48 hours.

• A. Rate control alone does not restore sinus rhythm and is less preferred in a young symptomatic patient with a reversible first episode within the safe cardioversion window.
• B. The 3-week anticoagulation delay strategy applies when onset is unknown or beyond 48 hours, not in this case.
• D. Transesophageal echocardiogram is unnecessary when onset is reliably within 48 hours.

Direct oral anticoagulants such as apixaban are preferred first-line over warfarin for stroke prevention in non-valvular atrial fibrillation due to comparable or superior efficacy, lower risk of intracranial hemorrhage, and no need for routine INR monitoring. Warfarin remains the agent of choice for patients with mechanical heart valves or significant mitral stenosis, neither of which this patient has. Heparin products are used for short-term parenteral anticoagulation, not for long-term stroke prevention in atrial fibrillation. This patient's normal renal function makes him a suitable candidate for a DOAC.

• A. Warfarin is reserved for patients with mechanical valves or significant mitral stenosis; DOACs are preferred in non-valvular atrial fibrillation.
• C. Low molecular weight heparin is not used for long-term stroke prevention in atrial fibrillation.
• D. Unfractionated heparin is used for short-term parenteral anticoagulation, not long-term stroke prevention in atrial fibrillation.

This patient shows signs of hemodynamic instability from tachyarrhythmia, including hypotension, altered mental status, and signs of poor perfusion, which mandates immediate synchronized electrical cardioversion rather than pharmacological rate or rhythm control. Delaying definitive treatment with intravenous drugs in an unstable patient risks further hemodynamic deterioration or cardiac arrest. Amiodarone and beta-blockers are used for rate or rhythm control in stable patients, not as first-line therapy for unstable tachyarrhythmia. Digoxin has a slow onset of action and is unsuitable for acute unstable presentations.

• B. Digoxin has a delayed onset of action and is not appropriate for immediate stabilization of an unstable tachyarrhythmia.
• C. Amiodarone has a slower onset and is used in stable patients or as an adjunct, not as first-line therapy for hemodynamic instability.
• D. Beta-blockers can worsen hypotension and are not appropriate first-line therapy in an unstable patient.

In a hemodynamically stable patient with regular narrow-complex supraventricular tachycardia that fails to respond to vagal maneuvers, intravenous adenosine is the first-line pharmacological agent, acting by transiently blocking conduction through the atrioventricular node to terminate the reentrant circuit. It has a very short half-life of less than 10 seconds, allowing rapid assessment of its effect with minimal prolonged side effects. Amiodarone and digoxin are not first-line for acute termination of stable SVT. Electrical cardioversion is reserved for hemodynamically unstable patients or when pharmacological therapy fails.

• B. Digoxin has a slow onset and is not used for acute termination of SVT.
• C. Amiodarone is not first-line for acute termination of stable SVT after failed vagal maneuvers.
• D. Electrical cardioversion is reserved for unstable patients or failure of pharmacological therapy, not as the immediate next step here.

This patient has ventricular tachycardia with signs of hemodynamic instability, including hypotension and altered mental status. Current ACLS guidelines mandate immediate synchronized cardioversion in unstable VT rather than trialing pharmacologic therapy, which is slower and less reliable in this setting. Amiodarone is used for stable VT or as an adjunct after cardioversion to prevent recurrence. Adenosine and vagal maneuvers are reserved for regular narrow-complex (supraventricular) tachycardias, not sustained wide-complex VT with instability.

• B. Adenosine is used for supraventricular tachycardia, not unstable VT, and delays definitive treatment.
• C. Antiarrhythmic infusion is too slow for an unstable patient and is reserved for stable VT.
• D. Vagal maneuvers are ineffective in ventricular tachycardia and inappropriate in an unstable patient.

The ECG description is classic for torsades de pointes, a polymorphic ventricular tachycardia occurring in the setting of QT prolongation, here likely due to the additive effect of a macrolide and a Class III antiarrhythmic (e.g., amiodarone or sotalol). Prolonged repolarization allows calcium channels to reopen during the prolonged plateau phase, generating early afterdepolarizations that trigger the arrhythmia. Management includes stopping the offending drugs, correcting electrolytes (especially magnesium and potassium), and giving intravenous magnesium sulfate even if serum magnesium is normal. This mechanism is distinct from re-entrant pathways, automaticity-driven focal tachycardias, or vagally mediated bradyarrhythmias.

• B. Accessory pathway re-entry causes pre-excited tachycardias, not polymorphic VT linked to QT prolongation.
• C. Increased vagal tone causes bradycardia, not a polymorphic tachyarrhythmia.
• D. Automaticity from ischemia produces monomorphic VT, not the twisting polymorphic pattern described.

This patient has symptomatic bradycardia with hypotension, dizziness, and poor perfusion, meeting criteria for unstable bradycardia requiring treatment. Atropine, an antimuscarinic agent, blocks vagal input to the sinoatrial and atrioventricular nodes, increasing the heart rate, and is recommended as first-line pharmacologic therapy per ACLS guidelines. If atropine fails or the bradycardia is due to high-degree AV block unresponsive to it, second-line options include transcutaneous pacing, dopamine, or epinephrine infusions. Isoproterenol is rarely used due to arrhythmogenic risk, and adenosine is contraindicated as it would worsen bradycardia.

• B. Dopamine is a second-line infusion used if atropine is ineffective.
• C. Adenosine slows AV conduction further and would worsen bradycardia.
• D. Isoproterenol is a second-line agent with significant arrhythmogenic potential, not first-line.

This presentation is classic for severe aortic stenosis, with the triad of angina, syncope, and exertional symptoms (often progressing to dyspnea or heart failure) reflecting a fixed outflow obstruction that limits cardiac output during exertion. The murmur is a harsh crescendo-decrescendo (ejection) systolic murmur at the right upper sternal border radiating to the carotids, accompanied by a delayed, weak carotid pulse (pulsus parvus et tardus) due to the fixed obstruction. Mitral stenosis produces a diastolic murmur, hypertrophic cardiomyopathy murmurs increase with Valsalva and have a brisk rather than delayed carotid upstroke, and aortic regurgitation causes a diastolic decrescendo murmur with a hyperdynamic pulse.

• A. Mitral stenosis causes a diastolic, not systolic, murmur best heard at the apex.
• B. Aortic regurgitation produces a diastolic murmur with widened pulse pressure, not this systolic pattern.
• C. Hypertrophic cardiomyopathy typically shows a brisk carotid upstroke and a murmur that increases with Valsalva, unlike the delayed upstroke here.

The holosystolic blowing murmur at the apex radiating to the axilla is characteristic of mitral regurgitation, and in a patient with a prior myocardial infarction, ischemic papillary muscle or chordal dysfunction causing malcoaptation of the mitral leaflets is a common etiology. Other important causes include mitral valve prolapse, myxomatous degeneration, infective endocarditis, and rheumatic heart disease, but the history of prior infarction makes ischemic papillary muscle dysfunction most likely here. Rheumatic disease more typically causes mitral stenosis with a diastolic murmur, though it can cause regurgitation as well, it is less consistent with this ischemic history. Aortic valve calcification causes aortic stenosis with a different murmur location and radiation, and pulmonary valve pathology is rare and produces a murmur at the pulmonic area.

• B. Rheumatic disease classically causes mitral stenosis with a diastolic murmur, and is less likely given the ischemic history.
• C. Pulmonary valve pathology is rare and produces a murmur at the left upper sternal border, not the apex.
• D. Aortic valve calcification causes a systolic murmur at the right upper sternal border radiating to the carotids, not the apex and axilla.

Diffuse ST elevation with concave morphology and PR segment depression, accompanied by positional pleuritic chest pain and a friction rub, is characteristic of acute pericarditis. The diagnosis requires at least two of four features: typical chest pain, friction rub, suggestive ECG changes, or a new pericardial effusion. Unlike myocardial infarction, the ST elevation is diffuse rather than localized to a vascular territory and is not accompanied by reciprocal depression. The clinical picture here fits an inflammatory pericardial process rather than an ischemic or vascular catastrophe.

• B. Aortic dissection causes tearing chest pain radiating to the back, not positional pleuritic pain with these ECG findings.
• C. Myocardial infarction produces territorial ST elevation with reciprocal changes, not diffuse changes with PR depression.
• D. Pulmonary embolism typically causes sinus tachycardia or right heart strain pattern, not diffuse ST elevation with PR depression.

Current guidelines recommend a combination of a high-dose NSAID, such as ibuprofen or aspirin, together with colchicine as first-line therapy for acute pericarditis. Colchicine reduces symptom duration and significantly lowers the rate of recurrence compared with NSAID monotherapy. Corticosteroids are reserved for cases with contraindications to NSAIDs, autoimmune etiology, or NSAID-colchicine failure, because early steroid use is associated with higher recurrence rates. Anticoagulation has no role and may worsen outcomes if hemorrhagic pericarditis or effusion is present.

• B. Anticoagulation is not indicated and could precipitate hemorrhagic transformation of a pericardial effusion.
• C. Paracetamol alone lacks the anti-inflammatory effect needed to treat the underlying pericardial inflammation.
• D. Corticosteroid monotherapy as first-line treatment increases the risk of recurrent pericarditis and is reserved for refractory or specific cases.

The combination of hypotension, elevated jugular venous pressure, and muffled heart sounds constitutes Beck's triad, classic for cardiac tamponade. An inspiratory drop in systolic blood pressure exceeding 10 mmHg, termed pulsus paradoxus, results from exaggerated interventricular dependence when pericardial fluid restricts cardiac filling. Malignancy is a common cause of pericardial effusion leading to tamponade. Echocardiography showing a pericardial effusion with diastolic right ventricular collapse and respiratory variation in ventricular filling would confirm the diagnosis.

• B. Heart failure typically presents with pulmonary crackles and a loud S3, not muffled heart sounds and pulsus paradoxus.
• C. Constrictive pericarditis presents subacutely with Kussmaul's sign rather than acute hypotension and pulsus paradoxus.
• D. Tension pneumothorax causes tracheal deviation and absent breath sounds on one side, not muffled heart sounds with Beck's triad.

Hemodynamically significant cardiac tamponade confirmed on echocardiography is a medical emergency requiring immediate pericardial fluid drainage, most commonly by echo-guided pericardiocentesis. This relieves the pressure compressing the heart and restores adequate ventricular filling and cardiac output. Intravenous fluids may be given temporarily to support preload while preparing for drainage, but they are not definitive treatment. Diuretics would worsen hypotension by further reducing preload, and this presentation is due to iatrogenic effusion, not recurrent ischemia.

• A. Corticosteroids have no role in the emergency management of hemodynamically significant tamponade.
• B. Coronary angiography addresses ischemia, not the mechanical compression caused by the pericardial effusion.
• C. Diuretics reduce preload further and can worsen hypotension in a preload-dependent tamponade state.

Chronic excessive alcohol intake is a well-recognized toxic cause of dilated cardiomyopathy, in which direct myocyte injury and oxidative stress lead to progressive ventricular dilation and impaired contractility. This produces systolic heart failure with a reduced ejection fraction, as seen in this patient's echocardiogram. Other causes of dilated cardiomyopathy include viral myocarditis, peripartum cardiomyopathy, genetic mutations, and certain chemotherapeutic agents such as doxorubicin. The hallmark finding is four-chamber dilation with reduced systolic function rather than a primary filling or infiltrative abnormality.

• B. Pericardial fibrosis describes constrictive pericarditis, which causes diastolic restriction, not ventricular dilation with reduced ejection fraction.
• C. Amyloid infiltration causes restrictive cardiomyopathy with preserved ejection fraction, not the dilated hypokinetic pattern described.
• D. Asymmetric septal hypertrophy describes hypertrophic cardiomyopathy, not the dilated, hypokinetic ventricle seen here.

Hypertrophic cardiomyopathy is the leading cause of sudden cardiac death in young athletes, typically resulting from ventricular arrhythmias triggered during intense exertion. The hallmark pathological finding is asymmetric septal hypertrophy with myocyte disarray and interstitial fibrosis, caused by autosomal dominant mutations in cardiac sarcomere genes. A family history of sudden death in a young relative strongly supports this diagnosis given its inherited pattern. Screening echocardiography is recommended for first-degree relatives of affected individuals.

• B. Anomalous coronary origin causes sudden death through ischemia, but it does not produce septal hypertrophy with myocyte disarray.
• C. Long QT syndrome is a channelopathy with a structurally normal heart, so it would not show septal thickening on autopsy.
• D. Myocarditis shows lymphocytic infiltration and myocyte necrosis on histology, not asymmetric septal hypertrophy with fiber disarray.

Innocent murmurs (such as Still's murmur) are typically soft (grade 1-2/6), musical or vibratory, have no associated thrill, and vary with position, usually becoming softer with standing or Valsalva due to decreased venous return. They are not associated with symptoms, abnormal pulses, or other signs of structural heart disease. Pathological murmurs are typically louder, harsh, holosystolic or diastolic, radiate widely, and are accompanied by thrills, abnormal second heart sounds, or systemic signs. Recognizing these benign features avoids unnecessary investigation and parental anxiety.

• A. Innocent murmurs typically soften, not intensify, with maneuvers that reduce venous return such as Valsalva strain.
• B. A holosystolic murmur radiating to the axilla suggests mitral regurgitation, a pathological finding.
• D. Fixed split S2 at the upper left sternal border suggests an atrial septal defect, a pathological finding.

The ankle-brachial index (ABI) is the recommended first-line, noninvasive test for suspected peripheral arterial disease presenting with classic intermittent claudication. An ABI of 0.90 or less confirms the diagnosis, with values between 0.41 and 0.90 indicating mild to moderate disease and 0.40 or less indicating severe disease. It is calculated by dividing the higher ankle systolic pressure by the higher brachial systolic pressure on each side. ABI is simple, inexpensive, and correlates well with disease severity, guiding further imaging or intervention decisions.

• A. Deep venous duplex evaluates venous thrombosis, not arterial insufficiency causing claudication.
• B. Resting ECG assesses cardiac rhythm and ischemia, not peripheral arterial perfusion.
• D. D-dimer is used to assess for venous thromboembolism, not arterial disease.

This patient has acute limb ischemia with features of pain, pallor, pulselessness, paresthesia, and paralysis (four of the six P's, with poikilothermia and sensory loss also present), indicating a threatened limb likely due to embolism from untreated atrial fibrillation. This is a vascular emergency requiring immediate vascular surgery consultation for urgent revascularization, as irreversible muscle and nerve damage can occur within 6 hours of ischemia onset. Anticoagulation with heparin should be started while awaiting surgery, but imaging or definitive therapy must not be delayed. Delayed treatment risks limb loss and systemic complications such as hyperkalemia and rhabdomyolysis.

• A. Discharge is unsafe given the risk of irreversible limb loss within hours without revascularization.
• C. Compression and elevation do not address the underlying arterial occlusion and may worsen ischemia.
• D. Oral warfarin has delayed onset and outpatient management is inappropriate for a threatened limb needing emergency intervention.

The combination of abrupt tearing chest pain radiating to the back, a significant blood pressure differential between arms, unequal pulses, and a new diastolic murmur (suggesting aortic regurgitation from dissection extending to the aortic root) is classic for acute aortic dissection. Hypertension is the leading risk factor. This presentation warrants urgent CT angiography of the aorta or transesophageal echocardiography to confirm the diagnosis and classify the dissection using the Stanford system, as management differs for type A versus type B dissection. Missing this diagnosis can be rapidly fatal due to aortic rupture or cardiac tamponade.

• A. Pneumothorax presents with sudden dyspnea and unilateral decreased breath sounds, not pulse and blood pressure asymmetry.
• B. Myocardial infarction typically does not cause a blood pressure differential between arms or an early diastolic murmur.
• C. Pulmonary embolism typically presents with dyspnea and pleuritic pain, not tearing interscapular pain with pulse differential.

In suspected aortic dissection, immediate priority is controlling heart rate and blood pressure to reduce aortic wall shear stress and limit propagation of the dissection, typically with an intravenous beta-blocker such as esmolol or labetalol, targeting a heart rate below 60 beats/min and systolic blood pressure of 100-120 mmHg. This should begin before or simultaneously with arranging urgent CT angiography, not delayed until imaging is complete. Vasodilators may be added after adequate beta-blockade to avoid reflex tachycardia, which would worsen shear stress. Thrombolytics and anticoagulation are contraindicated as they would worsen bleeding into the dissected aortic wall or mediastinum.

• A. Pain resolution does not exclude dissection, and discharge without definitive diagnosis is dangerous.
• B. Anticoagulation is contraindicated in aortic dissection due to the risk of worsening the intramural hemorrhage.
• C. Thrombolytics are contraindicated in aortic dissection as they increase the risk of fatal hemorrhage.

In patients with a moderate (intermediate) Wells score for deep vein thrombosis, the next step is to measure D-dimer level; a negative result effectively excludes DVT, while a positive result should prompt compression ultrasonography of the deep veins. This stepwise approach avoids unnecessary imaging in low-risk patients while ensuring high-risk or test-positive patients proceed to definitive duplex ultrasound. Contrast venography is invasive and reserved for cases where ultrasound is inconclusive. Empirical anticoagulation without further testing is not appropriate in a hemodynamically stable patient pending workup.

• A. Ventilation-perfusion scanning is used in the workup of pulmonary embolism, not deep vein thrombosis.
• B. Contrast venography is invasive and not first-line; it is reserved for cases where duplex ultrasound is equivocal.
• D. Empirical anticoagulation is not recommended before confirming the diagnosis in a hemodynamically stable patient with an intermediate pretest probability.

In a patient with a high pretest probability of pulmonary embolism based on Wells criteria (greater than 6 points), CT pulmonary angiography is the investigation of choice and should be performed directly, bypassing D-dimer testing, which is only useful to rule out PE in low or intermediate probability patients. D-dimer has low specificity and a positive result would not add diagnostic value when clinical suspicion is already high, risking a delay to definitive diagnosis and treatment. CTPA directly visualizes filling defects in the pulmonary arteries and allows prompt initiation of anticoagulation if positive. Chest radiograph and echocardiography may support the diagnosis but are not diagnostic or sufficiently sensitive for PE.

• A. Echocardiography can suggest right heart strain but is not diagnostic for pulmonary embolism.
• B. Chest radiograph is often normal or nonspecific in PE and cannot confirm the diagnosis.
• D. D-dimer is not useful in high pretest probability patients, as a negative result does not reliably exclude PE in this group.

The revised Jones criteria require evidence of a preceding group A streptococcal infection plus either two major criteria or one major and two minor criteria. This child has two major criteria: carditis (confirmed clinically with a new murmur and echocardiographically with valvulitis) and polyarthritis. Supporting evidence of antecedent streptococcal infection is present via the elevated ASO titer. In moderate- to high-risk populations, polyarthritis (rather than only polyarthralgia) counts as a major criterion, and echocardiographic valvulitis is accepted as part of the carditis criterion even without a classical holosystolic murmur description elsewhere.

• A. The combination of migratory polyarthritis with confirmed carditis and elevated acute phase reactants fulfills Jones criteria for rheumatic fever, not isolated reactive arthritis.
• C. This case has two major criteria (carditis and polyarthritis), not one major and two minor.
• D. Echocardiography has already confirmed active valvulitis, so the diagnosis can be made now, not deferred.

Office blood pressure thresholds for diagnosing hypertension are generally ≥140/90 mmHg on repeated visits, while ambulatory thresholds are lower: a 24-hour average ≥130/80 mmHg or daytime average ≥135/85 mmHg indicates hypertension. This patient has elevated office readings but normal ambulatory daytime (128/80 mmHg) and 24-hour (124/76 mmHg) averages, which is the classic pattern of white-coat hypertension. Guidelines recommend confirming office-diagnosed hypertension with out-of-office measurement (ambulatory or home monitoring) before starting lifelong pharmacologic therapy, because white-coat hypertension carries a better prognosis than sustained hypertension and does not routinely require drug treatment.

• B. Sustained hypertension requires elevation on both office and out-of-office measurement, which is not present here.
• C. Ambulatory monitoring is the reference standard used specifically to confirm or refute office-based diagnoses and is not invalid here.
• D. Masked hypertension is the opposite pattern: normal office readings with elevated ambulatory readings.

In patients of Black African or Caribbean descent without a compelling indication such as heart failure, chronic kidney disease, or diabetes with proteinuria, calcium channel blockers (or thiazide-like diuretics) are preferred first-line agents over ACE inhibitors or ARBs. This is because the renin-angiotensin system tends to be less active in this population, making ACE inhibitors and ARBs comparatively less effective at lowering blood pressure as monotherapy. Calcium channel blockers have robust outcome data for stroke and cardiovascular event reduction in this demographic and are well tolerated.

• A. Beta-blockers are not recommended as first-line therapy for uncomplicated essential hypertension in current guidelines.
• B. ACE inhibitors are typically less effective as monotherapy in Black patients without a compelling comorbidity due to lower renin activity.
• D. Centrally acting alpha-2 agonists are reserved for resistant hypertension or specific situations, not first-line therapy.

This patient has a hypertensive emergency, defined as severe blood pressure elevation with acute target-organ damage, here evidenced by papilledema and retinal hemorrhages (hypertensive retinopathy). Hypertensive emergencies require admission to a monitored setting with intravenous antihypertensive therapy such as labetalol, nicardipine, or sodium nitroprusside, with a controlled reduction in mean arterial pressure of about 10-20% in the first hour and a further gradual reduction over the next 23 hours to avoid hypoperfusion injury to the brain, heart, or kidneys. Hypertensive urgency, in contrast, involves severe BP elevation without acute organ damage and can be managed with oral agents and more gradual outpatient titration.

• A. Rapid oral agents like immediate-release nifedipine risk precipitous BP drops and are avoided in hypertensive emergencies.
• C. Aiming for a normal blood pressure within 30 minutes risks cerebral hypoperfusion and is not the recommended target.
• D. Discharge is inappropriate given evidence of acute target-organ damage requiring inpatient monitoring.